The elevated P/S ratio reflects a market expectation of future breakthrough rather than existing commercial traction. Given the lack of meaningful revenue, traditional valuation multiples like P/E or EV/EBITDA are non-informative, forcing investors to rely on the probability of successful CPT code integration and widespread clinical site onboarding.

The extreme negative margins suggest that the cost of maintaining the NOCISCAN-LS cloud engine and clinical support staff is currently decoupled from revenue generation. Until the company achieves a critical mass of paid scans, these margins will likely remain a significant drag on the overall financial profile.

The erratic nature of these returns suggests that capital is being deployed into long-term regulatory hurdles rather than high-yielding operational assets. Investors should monitor whether future capital allocation shifts toward commercialization, as current trends indicate a persistent decay in capital efficiency.

The extended collection period implies that the company lacks leverage over its customers, likely due to the nascent stage of its commercial relationships. This inefficiency in working capital management exacerbates the company's liquidity constraints and necessitates a more robust approach to revenue cycle management.